ArticleMaedica2024
The Investigation of Hearing Loss in Patients with Thalassemia Major Referred to Hazrat Ali Asghar (AS) Hospital in Sistan and Baluchistan Province (Iran).
Article in Maedica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hearing assessment in transfusion dependent beta-thalassemia children on oral iron chelating agent.BMC pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHearing disorders are one of the major complications in patients with thalassemia major. Therefore, the purpose of this research is to investigate hearing loss in patients with thalassemia major referred to Hazrat Ali Asghar Hospital in Sistan and Baluchistan province, Iran.
methodsThis cross-sectional descriptive study was conducted on 56 patients with thalassemia major who were referred to Ali Asghar Hospital in 2021-2022 and met the inclusion criteria into the present research. After obtaining the written consent of all participants, they underwent an audiometry test and were further examined. All information was collected in the researcher-made questionnaire and was analyzed using SPSS version 24 software.
resultsAmong the 56 eligible patients, 11 subjects (19.6%) had hearing loss. In terms of age, there was no statistically significant difference in hearing loss (P<0.05). Among the 11 patients with hearing loss, one patient (9.1%) had conductive hearing loss, three patients (27.3%) had sensorineural hearing loss, one patient (9.1%) had mixed hearing loss and six patients (54.5%) had hearing loss at frequencies above 5000 Hz. In terms of gender, there was no statistically significant difference in hearing loss. The average duration of Desferal in patients with hearing loss was significantly longer than other subjects (P<0.05).
conclusionTo prevent and treat hearing complications caused by thalassemia, regular and periodic hearing screening of all thalassemia patients is recommended.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.